PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
Public ClinicalTrials.gov record NCT03993379. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
Study identification
- NCT ID
- NCT03993379
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- CytomX Therapeutics
- Industry
- Enrollment
- 3 participants
Conditions and interventions
Conditions
Interventions
- CX-072 Drug
- Ipilimumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 19, 2019
- Primary completion
- May 20, 2020
- Completion
- May 20, 2020
- Last update posted
- Dec 25, 2025
2019 – 2020
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| The Angeles Clinic and Research Institute | Los Angeles | California | 90025 | — |
| Beacon Cancer Care | Coeur d'Alene | Idaho | 83814 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40202 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| NYC Cancer Institute | New York | New York | 10016 | — |
| Columbia Medical Center | New York | New York | 10032 | — |
| Oregon Health & Science Center | Portland | Oregon | 97210 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Inova Dwight and March Schar Cancer Institute | Fairfax | Virginia | 22031 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| Multicare Institute for Research and Innovation | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03993379, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 25, 2025 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03993379 live on ClinicalTrials.gov.